Cargando…

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND AND AIMS: Patients with diabetes mellitus frequently experience erectile dysfunction. This systematic review and meta-analysis were conducted to find efficacy and tolerability of phosphodiesterase 5 (PDE5) inhibitors in patients with diabetes mellitus experiencing erectile dysfunction. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balhara, Yatan Pal Singh, Sarkar, Siddharth, Gupta, Rishab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481650/ https://www.ncbi.nlm.nih.gov/pubmed/26180759 http://dx.doi.org/10.4103/2230-8210.159023

Ejemplares similares

Diabetes mellitus and suicide
por: Sarkar, Siddharth, et al.
Publicado: (2014)

Predictors of retention in treatment in a tertiary care de-addiction center
por: Majumder, Pradipta, et al.
Publicado: (2016)

Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report
por: Gupta, Prashant, et al.
Publicado: (2018)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Acute psychosis with a favorable outcome as a complication of central pontine/extrapontine myelinolysis in a middle aged man
por: Gupta, Rishab, et al.
Publicado: (2012)

Pathways to Care of Alcohol -Dependent Patients: An Exploratory Study From a Tertiary Care Substance Use Disorder Treatment Center
por: Pal Singh Balhara, Yatan, et al.
Publicado: (2016)

Does ICD-11 exclude the harm caused due to second hand and third hand smoke? - A critique
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2022)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Medical Use, Decriminalization, and Legalization of Narcotic Drugs and Psychotropic Substances—What Does It Mean and What Is Its Current Status in India?
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2022)

Correlates of anxiety and depression among patients with type 2 diabetes mellitus
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2011)

Use of Tramadol for Management of Opioid Use Disorders: Rationale and Recommendations
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2018)

Predictors of Inpatient Treatment Completion among Females with Opioid Use Disorder: Findings from a Tertiary Care Drug Dependence Treatment Centre of India
por: Dayal, Prabhoo, et al.
Publicado: (2017)

The “Hidden Story” about Change in Alcohol Use in India over the Past Two Decades: Insights from a Secondary Analysis of Data from the National Family Health Survey
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2021)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
por: Yuan, Jin-Qiu, et al.
Publicado: (2016)

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis
por: Yang, Jie, et al.
Publicado: (2021)

A randomized controlled trial of brief intervention for patients with cannabis use disorder
por: Shekhawat, Anil Singh, et al.
Publicado: (2023)

A Retrospective Chart Review of Treatment Completers Versus Noncompleters Among In-patients at a Tertiary Care Drug Dependence Treatment Centre in India
por: Sarkar, Siddharth, et al.
Publicado: (2016)

Quality of Life and its Relationship with Perceived Stigma among Opioid Use Disorder Patients: An Exploratory Study
por: Singh, Swarndeep, et al.
Publicado: (2018)

A Cross-sectional Study to Assess Disability and Its Correlates among Treatment Seeking Individuals with Alcohol Use Disorders
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2017)

Patterns and predictors of self-harm in patients with substance-use disorder
por: Gupta, Rishi, et al.
Publicado: (2019)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis
por: Stridh, Alexander, et al.
Publicado: (2020)

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction
por: Wang, Jian, et al.
Publicado: (2021)

The effectiveness of psychological interventions alone, or in combination with phosphodiesterase-5 inhibitors, for the treatment of erectile dysfunction:A systematic review
por: Atallah, Sandrine, et al.
Publicado: (2021)

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction
por: Cota, Jason M., et al.
Publicado: (2021)

Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis
por: Zhu, Jun, et al.
Publicado: (2020)

Diabetes and psychiatric disorders
por: Balhara, Yatan Pal Singh
Publicado: (2011)

Adult attention-deficit hyperactivity disorders and its correlates in patients with opioid dependence: An exploratory study
por: Gupta, Snehil, et al.
Publicado: (2020)

Reasons of Disciplinary Discharges from a Tertiary Care De-addiction Setting in India
por: Sarkar, Siddharth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hn6fs7tbjf6ksu7vdfjg49ms3l